Analyst Turns Bullish on KT as AI Investment Push Drives Rating Upgrade

KT Corporation, South Korea's second-largest telecommunications operator, has won a fresh vote of confidence from Wall Street after an analyst raised the rating on its New York-listed shares, framing the company's aggressive push into artificial intelligence as a meaningful turning point for investors.

The upgrade centers on KT's recently unveiled plan to pour billions of dollars into AI infrastructure. Under a new chief executive, the company has signaled its intent to move beyond its traditional identity as a network operator and reposition itself as an AI platform business, a shift the analyst views as a potential catalyst for the stock.

The investment program targets the buildout of computing power, data centers and cloud capabilities that underpin large-scale AI services. For a company long valued primarily for its stable but slow-growing telecom cash flows, the strategy offers a path toward higher-margin, faster-expanding revenue streams tied to the global AI boom.

KT's American Depositary Receipts trade on the New York Stock Exchange, giving international investors direct exposure to the Seoul-based operator. The bullish note argues that the market has yet to fully price in the earnings potential of the AI transition, leaving room for the shares to appreciate as the strategy takes shape.

The move mirrors a broader trend among South Korean technology and telecom firms racing to secure a foothold in AI, from chipmakers supplying advanced memory to platform companies building homegrown language models. KT has been positioning itself as a national AI champion, forging partnerships and committing capital to infrastructure it hopes will serve both domestic and enterprise customers.

Still, the ambitious spending carries execution risk. Heavy upfront investment could weigh on near-term profitability, and returns from AI infrastructure depend on sustained demand and disciplined capital allocation. For now, however, the analyst's upgrade reflects growing optimism that KT's reinvention could reward patient shareholders.